Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2022 | The importance of achieving CR before stem cell transplantation in patients with AML and ALL

Francesco Lanza • 24 Oct 2022
SOHO Italy 2022
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia

Francesco Lanza, MD, Romagna Transplant Network, Ravenna, Italy, explains why leukemic cells should ideally be eliminated from tissues before performing stem cell transplantation in patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), and further highlights the importance of carefully assessing measurable residual disease (MRD) in patients. This interview took place at the 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Francesco Lanza

How the AML treatment landscape is changing with the introduction of novel targeted agents
5:25
How the AML treatment landscape is changing with the introduction of novel targeted agents
Francesco Lanza • 24 Oct 2022
Optimizing biological agents for ALL
2:42
Optimizing biological agents for ALL
Francesco Lanza • 17 Sep 2020
Monoclonal antibody combinations in ALL
4:54
Monoclonal antibody combinations in ALL
Francesco Lanza • 17 Sep 2020

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals